39 research outputs found

    Caracterización nutricional de salsas a base de Xoconostle (Opuntia oligacantha C. F. Först)

    Get PDF
    Se elaboraron salsas a base de Xoconostle Ulapa, de la variedad Opuntia oligacantha C. F. Först, de un huerto comercial establecido en el municipio de Tezontepec de Aldama, Hidalgo, utilizando ingredientes como chile seco cascabel y, ajos, se obtuvieron en plantaciones establecidas en Zacatecas, Zac., MĂ©xico. Las salsas fueron elaboradas bajo la norma NMX-F-377-1986. Se obtuvieron cuatro tratamientos; con dos formulaciones (asada y cosida) y dos tratamientos tĂ©rmicos (marmita: 80°C durante 20 min y autoclave: 121°C durante 15 min); T1: Xoconostle cocido y tratamiento tĂ©rmico en autoclave, T2: Xoconostle asado y tratamiento tĂ©rmico en autoclave, T3: Xoconostle cocido y tratamiento tĂ©rmico en marmita, T4: Xoconostle asado y tratamiento tĂ©rmico en marmita. Las variables evaluaron fueron: pH, acidez titulable, color, grasas, carbohidratos, valor energĂ©tico, cenizas humedad, proteĂ­na y fibra cruda. Para el anĂĄlisis de resultados se utilizĂł el programa estadĂ­stico SAS, el diseño completamente al azar. Se realizĂł el anĂĄlisis de varianza y la prueba de comparaciones mĂșltiples de Tukey con una p≀0.05. El mayor contenido de sĂłlidos solubles totales o °Bx, se encontrĂł en la salsa de Xoconostle asada (A/m) y con tratamiento tĂ©rmico en marmita y tratamiento tĂ©rmico en autoclave (A/a), cenizas: en salsa de Xoconostle cocido y tratamiento tĂ©rmico en autoclave (C/a); el mayor contenido de humedad en salsa cocida y tratamiento tĂ©rmico en autoclave C/a y cocida y con tratamiento tĂ©rmico en marmita (C/m), proteĂ­na en A/m y C/a; y el mayor contenido de fibra cruda lo presento C/a

    Efecto de la temperatura sobre diferentes mieles multiflorales del estado de hidalgo en su actividad antibacteriana

    Get PDF
    Se determinó el efecto de la temperatura en la actividad antibacteriana de cinco mieles multiflorales del Estado de Hidalgo. Se recolectaron mieles de Acaxochitlan (AC), Arenal (AR), Huehuetla (HU), Orizatlan (OR) y Tasquillo (TA). Las determinaciones se realizaron por medio de bioensayos en los cuales se tenía una concentración inicial de 106 - 107 UFC/mL de las bacterias patógenas (Salmonella sp., B. subtillis, P. aeroginosa, L. monocytogenes) determinando la eliminación por el método de un vertido en placa. Todas las mieles fueron sometidas a diferentes temperaturas (40, 50, 60, 70 y 80 oC). Se observaron diferencias significativas (P<0.05) en el comportamiento de las diferentes mieles con respecto a la temperatura. En Salmonella sp se encontró un efecto lineal en todas las mieles, al incrementar la temperatura va descendiendo su actividad antibacteriana. Para B. subtillis y P. areroginosa el comportamiento de las mieles AR, TA y HU fue de forma lineal, mientras las mieles de OR y AC su comportamiento fue cuadråtico en donde a los 60°C se encuentra la mayor actividad antibacteriana. En cuanto a L. monocytogenes las mieles AC, AR, HU y OR se comportaron de forma cuadråtica, pero en la miel de TA se obtuvo un efecto lineal. Los resultados revelaron que las mieles se comportan de una manera diferente (lineal o cuadråtica) al ser sometidas a diferente temperatura y dependiendo de la bacteria patógena que estén eliminando

    Embracing monogenic Parkinson's disease: the MJFF Global Genetic PD Cohort

    Get PDF
    © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. Methods: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype-phenotype relationships were analyzed. Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Michael J. Fox Foundation for Parkinson's Research. Grant Number: ID 15015.02. NIHR Cambridge Biomedical Research Centre. Grant Number: BRC-1215-20014info:eu-repo/semantics/publishedVersio

    Biological invasion of European tomato crops by Tuta absoluta: ecology, geographic expansion and prospects for biological control

    Full text link

    The Helicobacter pylori Genome Project : insights into H. pylori population structure from analysis of a worldwide collection of complete genomes

    Get PDF
    Helicobacter pylori, a dominant member of the gastric microbiota, shares co-evolutionary history with humans. This has led to the development of genetically distinct H. pylori subpopulations associated with the geographic origin of the host and with differential gastric disease risk. Here, we provide insights into H. pylori population structure as a part of the Helicobacter pylori Genome Project (HpGP), a multi-disciplinary initiative aimed at elucidating H. pylori pathogenesis and identifying new therapeutic targets. We collected 1011 well-characterized clinical strains from 50 countries and generated high-quality genome sequences. We analysed core genome diversity and population structure of the HpGP dataset and 255 worldwide reference genomes to outline the ancestral contribution to Eurasian, African, and American populations. We found evidence of substantial contribution of population hpNorthAsia and subpopulation hspUral in Northern European H. pylori. The genomes of H. pylori isolated from northern and southern Indigenous Americans differed in that bacteria isolated in northern Indigenous communities were more similar to North Asian H. pylori while the southern had higher relatedness to hpEastAsia. Notably, we also found a highly clonal yet geographically dispersed North American subpopulation, which is negative for the cag pathogenicity island, and present in 7% of sequenced US genomes. We expect the HpGP dataset and the corresponding strains to become a major asset for H. pylori genomics

    BiotecnologĂ­a e inocuidad de los alimentos

    No full text
    Desde hace tiempo las aplicaciones de la biotecnologĂ­a han sido innumerables, desde la elaboraciĂłn de quesos, vinos, cervezas y pan, hasta la producciĂłn de medicamentos o nuevos alimentos. El desarrollo de tĂ©cnicas e instrumentos de investigaciĂłn biotecnolĂłgica han dado lugar a importantes descubrimientos y ademĂĄs han facilitado las aplicaciones en seres vivos para beneficio de la humanidad. Los paĂ­ses han adoptado distintos enfoques legislativos y no legislativos para reglamentar los alimentos obtenidos a partir de Organismos GenĂ©ticamente Modificados (OGM), por lo que los criterios que se utilizan para evaluar la inocuidad de estos productos suelen ser coherentes entre paĂ­ses. No obstante, la evaluaciĂłn de la inocuidad de los alimentos genĂ©ticamente modificados son procesos que se sitĂșan dentro del marco establecido para la evaluaciĂłn de riesgos. La evaluaciĂłn de la inocuidad es, fundamentalmente, el primer paso en la identificaciĂłn de cualquier peligro asociado a los alimentos, tras lo cual se evalĂșan los riesgos para la salud humana

    Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort.

    Get PDF
    BACKGROUND: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. OBJECTIVE: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. METHODS: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype-phenotype relationships were analyzed. RESULTS: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. CONCLUSIONS: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

    Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

    No full text
    BACKGROUND: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. OBJECTIVE: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. METHODS: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2 VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype-phenotype relationships were analyzed. RESULTS: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34\%) were indicated as not previously published. CONCLUSIONS: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
    corecore